We advised New Horizon Health on the top-up placement

Davis Polk advised New Horizon Health Limited on a top-up placement of 27,543,000 of its shares for a total consideration of approximately HK$781.7 million. 

Davis Polk also advised New Horizon Health Limited on its HK$2.04 billion IPO in February 2021.

New Horizon Health is the pioneer in China’s colorectal cancer screening market with ColoClear, its proprietary, non-invasive, multi-target, FIT-DNA test, being the first and only molecular cancer screening test in China approved by NMPA, according to Frost & Sullivan.

The Davis Polk team included partner Yang Chu and associates Sarah Shi and Michelle Chow. Members of the Davis Polk team are based in Hong Kong office.